Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients

Summary

A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.

Eligibility

Inclusion Criteria:

* 1\. Pathologically confirmed pancreatic ductal epithelial malignant tumors;
* 2\. Resectable pancreatic cancer treated with neoadjuvant chemoradiotherapy, or nonresectable locally advanced pancreatic cancer treated with neoadjuvant or radical chemoradiotherapy;
* 3.Nutritional Risk Screening 2002 (NRS2002) ≥3 and Patient-Generated Subjective Global Assessment (PG-SGA) performance status B;
* 4\. Age 18 years and older;
* 5\. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
* 6\. Expected survival time more than 3 months;
* 7\. History of antineoplastic therapy;

Exclusion Criteria:

* 1\. Known allergy or intolerance to any component of investigational Oral Immunonutrition;
* 2\. History of Oral Immunonutrition use within one month prior to enrollment;
* 3\. Tumor compresses the major duodenal papilla, and /or appeared jaundice, acute pancreatitis;
* 4\. Patients with contraindications for antineoplastic therapy, such as coronary heart disease, cerebral infarction, cerebral hemorrhage or other serious diseases;
* 5\. Liver, kidney and blood coagulation function failure;
* 6\. Patients with hemopathy;
* 7\. Patients with active infections;
* 8\. Patients with other primary tumor;
* 9\. Patients with other medical diseases that seriously affected nutritional status;
* 10.Subjects deemed by the investigator have other factors that may be ineligible for enrollment;

Conditions4

Browse More Trials